The potent triarylethylene pharmacophore

Drugs of the Future

Volumn 29, Issue 2, 2004, Pages 185-203

  Ray, Suprabhat ^a   Sangita, ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (2 DIETHYLAMINOETHOXY)PHENYL] 2 (4 METHOXYPHENYL) 1 PHENYLETHANE; ARZOXIFENE; CENTCHROMAN; CLOMIFENE CITRATE; DIETHYLSTILBESTROL; DROLOXIFENE; ENCLOMIFENE; ESTROGEN; ESTROGEN DERIVATIVE; ETHAMOXYTRIPHETOL; ETHYLENE DERIVATIVE; FC 1271 A; IDOXIFENE; LASOFOXIFENE; MIPROXIFENE PHOSPHATE; NAFOXIDINE; NAPHTHALENE DERIVATIVE; NITROMIFENE; OSPEMIFENE; PHENYLBUTAZONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TOREMIFENE; TRIOXIFENE; U 10520; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZUCLOMIFENE;

AGONIST; BREAST CANCER; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTRACEPTION; DIZZINESS; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ESTROGEN ACTIVITY; FATIGUE; FERTILITY; GENOTOXICITY; HEADACHE; HOT FLUSH; HUMAN; INFERTILITY; LEG CRAMP; LOW DRUG DOSE; NAUSEA; NERVOUSNESS; NONHUMAN; OSTEOPOROSIS; OVARY HYPERTROPHY; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VISUAL DISORDER; VOMITING;

EID: 1642360838     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.02.780099     Document Type: Review

References (218)

1. Dodds, E.C., Goldberg, L., Lawson, W., Robinson, R. Estrogenic activity of esters of diethyl stilboestrol. Nature 1938, 142: 211-2.
2. Dodds, E.C., Goldberg, L., Lawson, W., Robinson, R. Estrogenic activity of certain synthetic compounds. Nature 1938, 141: 247-8.
3. Grundy, J. Artificial estrogens. Chem Rev 1957, 57: 281-416.
4. Lerner, L.J., Holthaus, F.J. Jr., Thompson, C.R. A nonsteroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxy-phenyl ethanol. Endocrinology 1958, 63: 295-318.
5. Segal, J.S., Nelson, W.O. An orally active compound with antifertility effects in rats. Proc Soc Exp Biol Med 1958, 98: 431-6.
6. Segal, S.J., Nelson, W.O. Antifertility action of chloramiphene. Anat Rec 1961, 139: 273.
7. Smith, O.W., Smith, G.V., Kistner, R.W. Action of MER-25 and of clomiphene on the human ovary. JAMA - J Am Med Assoc 1963, 184: 878-86.
8. Allen, R.E., Palopoli, F.P., Schumann, E.L., Campen, M.G.V. Jr. Amine derivatives of triphenylethanol, triphenylethylene and triphenylethane. US 2914561.
9. Greslin, J.G., Van Maanen, E.F., Davis, R.H., Holtcamp, D.E. 41st Meet Endocrine Soc 1959, 82.
10. Holtkamp, D.E., Greslin, J.G., Root, C.A., Lerner, L.J. Gonadotrophin inhibiting and anti-fecundity effects of chloramiphene. Proc Soc Exp Biol Med 1960, 105: 197-201.
11. Roy, S., Greenblatt, R.B., Mahesh, V.B. Effects of clomiphene on the physiology of reproduction in the rat. II. Its oestrogenic and antioestrogenic action. Acta Endocr 1964, 47: 657-66.
12. Gaunt, R., Chart, J.J., Renzi, A.A. Endocrine pharmacology. Science 1961, 133: 613-21.
13. Chakraborty, P.K., Brown, J.L., Ruff, C.B., Nelson, M.F., Mitchell, A.S. Effects of long term treatment with estradiol or clomiphene citrate on bone maintenance and pituitary and uterine weights in ovariectomized rats. J Steroid Biochem Mol Biol 1991, 40: 725-9.
14. Jordan, V.C., Phelps, E., Lindgren, J.U. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987, 10(1): 31-5.
15. Beall, P.T., Misra, L.K., Young, R.L., Spjut, H.J., Evans, H.J., Leblanc, A. Clomiphene protects against osteoporosis in the mature ovarietomized rat. Calcif Tissue Int 1984, 36(1): 123-5.
16. Dewald, H.A., Bird, O.D., Rodney, G., Kaump, D.H., Black, M.L. Pharmacology of a new class of orally effective antifertility agents with hypocholesteraemic activity. Nature 1966, 211: 538-9.
17. Callantine, M.R., Humphrey, R.R., Lee, S.L., Windsor, B.L., Schottin, N.H., O'Brien, O.P. Action of an estrogen antagonist on reproductive mechanisms in the rat. Endocrinology 1966, 79: 153-67.
18. Harper, M.J.K., Walpole, A.L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 1966, 212: 87.
19. Harper, M.J.K., Walpole, A.L. Mode of action of I.C.I. 46,474 in preventing implantation in rats. J Endocrinol 1967, 37(1): 83-92.
20. Harper, M.J.K., Walpole, A.L. A new derivative of triphenylethylene: Effect on implantation and mode of action in rats. J Reprod Fert 1967, 13(1): 101-19.
21. Kusuhara, S., Ishida, K. Influence of sexual hormones on the secretory rate in uropygial glands of cockerels. Nippon Chikusan Gakkaiho 1984, 55(10): 760-4.
22. Turner, R.T., Wakley, G.K., Hannon, K.S., Bell, N.H. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 1987, 2(5): 449-56.
23. Dwivedi, I., Ray, S. Recent developments in the chemotherapy of osteoporosis. Prog Drug Res 1995, 45: 289-338.
24. Ward, R.L., Morgan, G., Dally, D., Kelly, P.J. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 1993, 22: 87-94.
25. Love, R.R., Barden, H.S., Mazess, R.B., Epstein, S., Chappell, R.J. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994, 154: 2585-8.
26. Turner, R.T., Wakley, G.K., Hannon, K.S., Bell, N.H. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 1988, 122: 1146-50.
27. Evans, G.L., Turner, R.T. Tissue selective actions of estrogen analogs. Bone 1995, 17(Suppl.): 181S-90S.
28. Levenson, A.S., Jordan, V.C. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium. Eur J Cancer 1999, 35(14): 1974-85.
29. Van Paassen, H.C., Poortman, J., Borgart-Creutzburg, I.H.C., Thijssen, J.H.H., Duursma, S.A. Estrogen binding proteins in bone cell cytosol. Calcif Tissue Res 1978, 25(3): 249-54.
30. Gray, T.K., Flynn, T.C., Gray, K.M., Nabell, L.M. 17beta-Estradiol acts directly on the clonal osteoblastic cell line UMR106. Proc Natl Acad Sci USA 1987, 84(17): 6267-71.
31. Eriksen, E.F., Colvard, D.S., Berg, N.J., Graham, M.L., Mann, K.G., Spelsberg, T.C., Riggs, B.L. Evidence of estrogen receptors in normal human osteoblast like cells. Science 1988, 241: 84-6.
32. Komm, B.S., Terpening, C.M., Benz, D.J. et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988, 241: 81-4.
33. Gold, E., Stapley, S., Goulding, A. Tamoxifen and norethisterone: Effects on plasma cholesterol and total body calcium content in the estrogen deficient rat. Horm Metab Res 1994, 26(2): 100-3.
34. Gradishar, W.J., Jordan, V.C. Clinical potential of new antiestrogens J Clin Oncol 1997, 15(2): 840-52.
35. Kauffman, R.F., Bryant, H.U. Selective estrogen receptor modulators. Drug News Perspect 1995, 8: 531-8.
36. Schickaneder, H., Loeser, R., Grill, H. (Fujisawa Deutschland GmbH). 1,1,2-Triphenylbut-1-ene derivatives and their use as pharmaceutical agents. EP 0054168.
37. Roos, W., Oeze, L., Loeser, R., Eppenberger, U. Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7. J Natl Cancer Inst 1983, 71(1): 55-9.
38. Hasmann, M., Rattel, B., Loeser, R. Preclinical data for droloxifene. Cancer Lett 1994, 84(2): 101-16.
39. Tominaga, T., Yoshida, Y., Matsumoto, A., Hayashi, K., Kosaki, G. Effects of tamoxifen and the derivative TAT on cell cycle of MCF-7 in vitro. Anticancer Res 1993, 13(3): 661-5.
40. Rauschning, W., Pritchard, K.I. Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Treat 1994, 31: 83-94.
41. Bellmunt, J., Sole, L. European early phase II dose finding study of droloxifene in advanced breast cancer. Am J Clin Oncol 1991, 14: S36-9.
42. Haarstad, H., Gundersen, S., Wist, E. et al. Droloxifene: A new anti-estrogen. Phase II study in advanced breast cancer. Acta Oncol 1992, 31: 425-8.
43. Ke, H.Z., Simmons, H.A., Pirie, C.M. et al. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 1995, 136: 2435-41.
44. Fontana, S.A. Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives (Eli Lilly and Co.) US 5455275.
45. a) McCague, R., Potter, G.A., Jarman, M. An efficient, large-scale synthesis of idoxifene ((E)-1-[4-[N-(pyrrolidino)ethoxy] phenyl]-1-(4-iodophenyl)-2-phenyl-1-buten. Org Prep Proceed Int 1994, 26(3): 343-6.
46. b) McCague, R. (National Research Development Corporation). Tamoxifen derivatives. EP 0260066.
47. McCague, R., Parr, I.B., Haynes, B.P. Metabolism of the 4-iododerivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites. Biochem Pharmacol 1990, 40 (10): 2277-83.
48. Idoxifene. Drugs Fut 1999, 24(7): 804-6.
49. Toivola, R.J., Karjalainen, A.J., Kurkela, K.O.A., Sodervall, M.L., Kangas, L.V.M., Blanco, G.L., Sundquist, H.K. Novel triphenyl alkane and alkene derivatives and their preparation and use. (Farmos Group Ltd.). EP 0095875, FI 821879.
50. a) Asao, T., Takeda, S., Sugimoto, Y., Toko, T., Yamada, Y., Ogawa, K., Unemi, N. (Taiho Pharmaceutical Co., Ltd.). 1,1,2-Triaryl-1-butene derivatives. WO 8707609.
51. b) Hoshi, A. TAT-59. Drugs Fut 1991, 16(3): 217-9.
52. a) Toko, T., Sugimoto, Y., Matsuo, K., Yamasaki, R., Takeda, S., Wierzba, K., Asao, Y., Yamada, Y. TAT-59, a new triphenylethylene derivative with antitumor activity against hormone dependent tumors. Eur J Cancer 1990, 26(3): 397-404.
53. b) Koh, J.I., Kubota, T., Asanuma, F. et al. Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice. J Surg Oncol 1992, 51: 254-8.
54. c) Iino, Y., Takai, Y., Ando, T. et al. A new triphenylethylene derivative, TAT-59; hormone receptors; insulin like growth factor 1; and growth suppression of hormone dependent MCF-7 tumors in athymic mice. Cancer Chemother Pharmacol 1994, 34(5): 372-6.
55. Toko, T., Matsuo, K-I., Shibata, J. et al. Interaction of DP-TAT-59, an active metabolite of new triphenylethylene-derivative (TAT-59), with estrogen receptors J Steroid Biochem Mol Biol 1992, 43(6): 507-14.
56. Degregorio, M., Kangas, L.V.M., Härkönen, P., Väänänen, K., Laine, A., Wiebe, V. (Orion Corp.). Triphenylethylenes for the prevention and treatment of osteoporosis. WO 9607402.
57. a) Voipio, S.K., Komi, J., Kangas, L., Halonen, K., DeGregorio, M.W., Erkkola, R. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002, 43 (3): 207-14.
58. b) Taras, T.L., Wurz, G.T., DeGregorio, M.W. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer J Steroid Biochem Mol Biol 2001, 77(4-5): 271-9.
59. Day, B.W., Magarian, R.A., Jain, P.T., Pento, J.T., Mousissian, G.K., Meyer, K.L. Synthesis and biological evaluation of a series of 1,1-dichloro-2,2,3-triarylcyclopropanes as pure antiestrogens. J Med Chem 1991, 34: 842-51.
60. Hossain, M.B., van der Helm, D., Schmitz, F.J. et al. Molecular structures and conformational studies of triarylcyclopropyl and related nonsteroidal antiestrogens. J Med Chem 1994, 37: 1670-83.
61. Lednicer, D., Babcock, J.C., Lyster, S.C., Stucki, J.C., Duncan, G.W. Derivatives of 2,3-diphenylindenes as antifertility agents. Chem Ind 1961, 2098-9.
62. Lednicer, D., Babcock, J.C., Marlatt, P.E., Lyster, S.C., Duncan, G.W. Mammalian antifertility agents. 1. Derivatives of 2,3-diphenylindenes. J Med Chem 1965, 8: 52-7.
63. Duncan, G.W., Stucki, J.C., Lyster, S.C., Lednicer, D. An orally effective mammalian antifertility agents. Proc Soc Exp Biol Med 1962, 109: 163-6.
64. Morris, J.M., van Wagenen, G., McCann, T., Jacob, D. Compounds interfering with ovum implantation and development. II. Synthetic estrogens and antiestrogens. Fertil Steril 1967, 18(1): 18-34.
65. Malik, M.S., Rastogi, S.N. Studies in antifertility agents: Part XXXV - Synthesis of 1,2-trans-1-[p-(β-pyrrolidinoethoxy) phenyl]-2-phenyl-5-methoxyindane. Ind J Chem 1981, 20B: 174-5.
66. Malik, M.S., Rastogi, S.N., Singh, M.M., Sreenivasulu, S., Agnihotri, A., Kalra, V., Kamboj, V.P. Antifertility agents 45. Synthesis and activity of 1,2-cis-1-(p-(β-pyrrolidino ethoxy) phenyl)-2-phenyl-5-methoxyindane. Eur J Med Chem 1989, 24: 193-7.
67. Bencze, W.L., Carney, R.W.J., Barsky, L.I., Renzi, A.A., Dorfman, L., De Stevens, G. Synthetic estrogens and implantation inhibitors. Experientia 1965, 21: 261.
68. Lednicer, D., Babcock, J.C., Lyster, S.C., Duncan, G.W. Derivatives of 1,2-diphenyl-3,4-dihydronaphthalene as antifertility agents. Chem Ind 1963, 408-9.
69. Duncan, G.W., Lyster, S.C., Clark, J.J. Lednicer, D. Antifertility activities of two diphenyl-dihydronaphthalene derivatives. Proc Soc Exp Biol Med 1963, 112: 439-42.
70. Lednicer, D., Lyster, S.C., Duncan, G.W. Mammalian antifertility agents. IV. Basic 3,4-dihydronaphthalenes and 1,2,3,4-tetrahydro-1-naphthols. J Med Chem 1967, 10: 78-84.
71. a) Cameron, K.O., Jardine, P.A. DaSilva., Rosati, R.L. (Pfizer, Inc.). Estrogen agonists/antagonists. WO 9621656.
72. b) Rosati, R.L., Jardine, P.D.S., Cameron, K.O. et al. Discovery and preclinical pharmacology of novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 1998, 41: 2928-31.
73. Ke, H.Z., Paralkar, V.M., Grasser, W.A. et al. Effects of CP-336, 156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998, 139: 2068-76.
74. a) Sorbera, L.A., Leeson, P.A., Castañer, J. CP-336,156. Drugs Fut 1998, 23(10): 1066-70.
75. b) Ke, H.Z., Qi, H., Chidsey-Frink, K.L., Crawford, D.T., Thompson, D.D.J. Lasofoxifene (CP-336, 156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. Bone Miner Res 2001, 16(4): 765-73.
76. Malik, M.S., Rastogi, S.N. Studies on antifertility agents: Part XLII - Synthesis and antifertility study of 6-methoxy-3-phenyl-1-[p-(β -pyrrolidinoethoxy) phenyl] tetralin. Ind J Chem 1984, 23B: 834-8.
77. Srivastava, N., Singh, M.M., Ray, S. A process for the synthesis of secondary amino alkoxy derivatives of substituted diaryl 1,2,3,4-tetrahydronaphthyl methane. Patent no. 232/DEL/98, 28.1.1998.
78. Srivastava, N., Singh, M.M., Ray, S. A process for the preparation of tertiary amino alkoxy derivatives of substituted diaryl 1,2,3,4-tetrahydronaphthyl methane as fertility regulating agents and their salts. Patent no. 234/DEL/98, 28.1.1998.
79. Sung-Hoon, K., Katzenellenbogen, J.A. Triarylethylene bisphenols with a novel cycle are ligands for the estrogen receptor. Bioorg Med Chem 2000, 8: 785-93.
80. McCague, R., Leclercq, G., Jordan, V.C. Nonisomerizable analogues of (Z)- and (E)-4-hydroxy tamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes. J Med Chem 1988, 31: 1285-90.
81. Sangwan, N.K., Prasad, M., Rastogi, S.N., Jehan, Q., Setty, B.S. Antifertility agents: Part XLVI - Synthesis and activity of 1,2-trans-1-[p-(β-pyrrolidinoethoxy) phenyl]-2-phenyl-7-methoxybenzosuberan. Ind J Chem 1986, 25B: 832-7.
82. Iyer, R.N., Gopalchari, R. Studies in potential antifertility agents: Part II - Synthesis of some derivatives of indoles and related compounds Ind J Chem. 1966, 4: 520-3.
83. Landquist, J.K., Marsden, C.J. Tertiary aminoalkyl derivatives of 2,3-diphenyl indole. Chem Ind 1966, 1032-3.
84. Grover, P.K., Chawla, H.P.S., Anand, N., Kamboj, V.P., Kar, A.B. New antifertility agents. 2,3-Diphenyl-benzofurans. J Med Chem 1965, 8: 720-1.
85. Chawla, H.P.S., Grover, P.K., Anand, N., Kamboj, V.P., Kar, A.B. Antifertility agents. IV. 2,3-Diphenylbenzo-and 5,6-polymethylenebenzofurans, 1,2-diphenylnaphthofurans and some related compounds. J Med Chem 1970, 13: 54-9.
86. Gupta, R.C., Srivastava, S.C., Anand, N. Studies on antifertility agents: Part XVIII - 2,3-Diarylphenanthrofurans and some related compounds. Ind J Chem 1977, 15b: 91-2.
87. Lednicer, D., Lyster, S.G., Duncan, G.W. Mammalian antifertility agents. II. Basic ethers of 3,4-diphenyl coumarins. J Med Chem 1965, 8(5): 725-6.
88. Anand, N., Ray, S. Centchroman - A postcoital contraceptive agent. Ind J Exp Biol 1977, 15: 1142-3.
89. Salman, M., Arora, P.K., Ray, S., Srimal, R.C. 3,4-Diarylcoumarins, chromenes and chromans, as novel antiinflammatory agents. Ind J Pharm Sci 1987, 49: 43-7.
90. Ray, S., Singh, M.M., Agarwal, A.K., Kamboj, V.P. Enhanced antifertility activity of non-steroidal molecules with 3-n-butyl-amino-2-hydroxy propyloxy side chain. Contraception 1987, 35: 283-7.
91. Carney, R.W.J., Bencze, W.L., Wojtkunski, J., Renzi, A.A., Dorfman, L., DeStevens, G. Derivatives of 3,4-diphenylchromans as estrogens and implantation inhibitors. J Med Chem 1966, 9: 516-20.
92. Ray, S., Grover, P.K., Kamboj, V.P., Setty, B.S., Kar, A.B., Anand, N. Antifertility agents. 12. Structure-activity relationship of 3,4-diphenylchromenes and chromans. J Med Chem 1976, 19: 276-9.
93. Kole, P.L., Ray, S., Anand, N. Studies in antifertility agents. Part XX: 2,3-Cis-3,4-cis- and 2,3-trans-3,4-trans-2-methyl-3-phenyl-4-[4-(2-pyrrolidinoethoxy)] phenyl-4-7-methoxychroman. Ind J Chem 1978, 16B: 722-3.
94. Ray, S., Grover, P.K., Anand, N. A new synthesis of cis- and trans- 3-phenyl-4-[4-(2-pyrrolidinoethoxy)] phenyl 7-methoxychromans. Ind J Chem 1971, 9: 727-8.
95. Durani, S., Agarwal, A.K., Saxena, R., Setty, B.S., Gupta, R.C. Kole, P.L., Ray, S., Anand, N. Seco-oestradiols and some non-steroidal oestroges: Structural correlates of oestrogenic action. J Steroid Biochem 1979, 11: 67-77.
96. Ray, S., Tandon, A., Dwivedi, I., Wilson, S.R., O' Neil, J.P., Katzenellenbogen, J.A. An X-ray crystallographic study of the non-stroidal contraceptive agent centchroman. J Med Chem 1994, 37: 696-700.
97. Prasad, S. Centchroman: A novel drug for DUB. J Obstet Gynecol India 2000, 50: 77-9.
98. Subramanium, U., Gupte, S.A., Gupte, A.S. Centchroman in AUB. Proc 43rd ALL India Cong Obstet Gynecol (Dec 26-30, Lucknow) 1999, 28.
99. a) Bain, S.D., Celino, D.L., Baily, M.C., Strachan, M.J., Piggott, J.R., Labroo, V.M. Centchroman, a nonsteroidal antiestrogen, is a bone-specific estrogen agonist in the ovariectomized rat. Calcif Tissue Int 1995, 54: 338.
100. b) Hall, T.J., Nyugen, H., Schaueblin, M., Fournier, B. The bone-specific estrogen centchroman inhibits osteoclastic bone resorption in vitro. Biochem Biophys Res Commun 1995, 216: 662-8.
101. Bain, S.D., Grennspan, D., Kurman, R., Shalmi, M., Guldhammer, B., Korsgaard, N. Levormeloxifene, a nonsteroidal, partial estrogen agonist, prevents bone loss, reduces serum cholesterol and exerts a nonproliferative action on uterine tissue in the ovariectomized rat. J Bone Miner Res 1997, 12(Suppl. 1): Abst F484.
102. Nowak, J., Festersen, U., Andersen, A., Christensen, N.D. Effect of levormeloxifene, a partial estrogen receptor agonist, on serum cholesterol, osteocalcin and bone in the ovariectomized rat. J Bone Miner Res 1997, 12(Suppl. 1): Abst F483.
103. Nowak, J., Sjogren, I., Festersen, U., Christensen, N.D. Effect of levormeloxifene, a partial estrogen receptor agonist, on body weight and food conversion efficacy, and uterus in the ovariectomized rat. J Bone Miner Res 1997, 12(Suppl. 1): Abst F482.
104. Sato, M., Grese, T.A., Dodge, J.A., Bryant, H.U., Turner, C.H. Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem 1999, 42: 1-24.
105. Bjarnason, K., Skrumsager, B.K., Kiehr, B., Pederson, P.C. Levormeloxifene, a new partial estrogen receptor agonist, demonstrates antiresorptive and antiatherogenic properties in post-menopausal women. J Bone Miner Res 1997, 12(Suppl. 1): Abst F479.
106. Novo Nordisk discontinues development of osteoporosis drug. DailyDrugNews.com (Daily Essentials) 1998, September 28.
107. a) Jacobsen, P., Treppendahl, S., Bury, P.S., Kanstrup, A., Christiansen, L.B. Novel (-) enantiomers of cis-3,4-chroman prevention or treatment of estrogen related diseases. WO 9818771.
108. b) Bury, P.S., Christiansen, L.B., Jacobsen, P. et al. Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg Med Chem 2002, 10(1): 125-45.
109. Ray, S., Grover, P.K., Anand, N. Antifertility agents: Part V - Synthesis of 2,2-dimethyl-3,4-diphenyl-5,6-benzochromenes and 1,1-dimethyl-2,3-diphenylphenalines. Ind J Chem 1970, 8: 961-3.
110. Pruitt, V.L., Berlin, K.D., Hirsch, K.S. Synthesis of some 3,4-dihydro-2H-1-benzothiopyran-4-ols. Org Prep Proc Int 1990, 22(2): 235-44.
111. Crenshaw, R.R., Witt, De. Substituted 3,4-dihydro-3-phenyl-4-hydroxy-4-{[(amino) alkoxy (or alkylthio)] phenyl} isothiochroman. US 3332956.
112. Iyer, R.N., Gopalchari, R. Studies in potential antifertility agents: Part III: Synthesis of basic ethers from phenolic 2,3-diphenylacrylophenone and related compounds. Ind J Pharm 1969, 31: 49-54.
113. Gopalchari, R., Iyer, R.N., Kamboj, V.P., Kar, A.B. Antifertility agents: Part V: 3-Alkyl-2,3-diphenyl propiophenones. Contraception 1970, 2(3): 199-205.
114. Mehrotra, P.K., Karkun, J.N. Estrogenic and antiestrogenic properties of E-492, nonsteroidal compound. Ind J Exp Biol 1975, 13(1): 69-70.
115. Gopalchari, R., Iyer, R.N., Kamboj, V.P., Kar, A.B. Antifertility agents: 1,2,3- Triphenylpropenes. VI. Ind J Exp Biol 1971, 9(1): 104-5.
116. Meegan, M.J., Hughes, R.B., Lloyd, D.G., Williams, D.C., Zisterer, D.M. Flexible estrogen receptor modulators: Design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells. J Med Chem 2001, 44: 1072-84.
117. Jones, C.D., Suarez, T., Massey, E.H., Black, L.J., Tinsley, F.C. Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl] [4-[2-(1-pyrrolidinyl)ethoxy]-phenyl] methanone, methanesulfonic acid salt. J Med Chem 1979, 22: 962-6.
118. Black, L.J., Jones, C.D., Falcone, J.F. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983, 32: 1031-6.
119. Black, L.J., Goode, R.L. Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY 117018) in rats and mice. Life Sci 1980, 26: 1453-8.
120. Wakeling, A.E., Valcaccia, B. Antiestrogenic and antitumour activities of a series of nonsteroidal antiestrogens. J Endocrinol 1983, 99: 455-64.
121. a) Palkowitz, A.D., Thrasher, K.J. (Eli Lilly and Company). Benzothiophene compounds, intermediate and methods. EP 0729956.
122. b) Palkowitz, A.D., Glasebrook, A.L., Thrasher, K.J. et al. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)-ethoxy] phenoxy]-2-(4-hydroxyphenyl)] benzo [b] thiophene: A novel, highly potent, selective estrogen receptor modulator. J Med Chem 1997, 40(10): 1407-16.
123. Rabasseda, X., Leeson, P.A., Castañer, J. Arzoxifene hydrochloride. Drugs Fut 1999, 24(6): 599-604.
124. Hudis, C., Buzdas, A., Munster, P. et al. Preliminary results of a phase I study of a third generation selective estrogen receptor modulator (SERM 3, LY353381. HCI) in refractory, metastatic breast cancer. Cancer Invest 1999, 17(Suppl. 1): Abst 43.
125. Sharma, A.P., Saeed, A., Durani, S., Kapil, R.S. Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. J Med Chem 1990, 33(12): 3222-9.
126. Sharma, A.P., Saeed, A., Durani, S., Kapil, R.S. Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2,3-diaryl-2H-1-benzopyrans. J Med Chem 1990, 33(12): 3216-21.
127. Saeed, A., Sharma, A.P., Durani, N., Jain, R., Durani, S., Kapil, R.S. Structure-activity relationship of antiestrogens. Studies on 2,3-diaryl-1-benzopyrans. J Med Chem 1990, 33(12): 3210-6.
128. Bryant, H.U., Grese, T.A. (Eli Lilly and Company). Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans. US 5407947.
129. Hajela, K., Pandey, J., Dwivedi, A., Dhar, J.D., Sarkhel, S., Maulik, P.R., Velumurugan, D. Resolution, molecular structure and biological activities of the d- and l-enantiomers of potent anti-implantation agent, dl-2-[4-(2-piperidinoethoxy) phenyl]-3-phenyl-2H-1-benzopyran. Bioorg Med Chem 1999, 7: 2083-90.
130. a) Labrie, F., Merand, Y. (Endorecherche Inc.). Sex steroid activity inhibitors. WO 9310741.
131. b) Labrie, F., Merand, Y., Gauthier, S. (Endorecherce Inc.). Benzopyran-containing compound for their use. WO 9626201.
132. Martel, C., Picard, S., Richard, V., Belanger, A., Labrie, C., Labrie, F. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Mol Biol 2000, 74: 45-56.
133. Tremblay, A., Tremblay, G.B., Labrie, C., Labrie, F., Giguére, V. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and β. Endocrinology 1998, 139(1): 111-8.
134. a) Dikshit, D.K., Munshi, K.L., Kapil, R.S., Kamboj, V.P., Anand, N. Antifertility agents: Part IX - Synthesis of 2,3,4-triphenylfurans and 2,3,4-triphenyl-5- methylfurans. Ind J Chem 1974, 12: 1144-6.
135. b) Munshi, K.L., Dikshit, D.K., Kapil, R.S., Anand, N. Synthesis of 2,3-trans-3,4-cis-and 2,3-trans-3,4-trans2,3,4-triphenyltetrahydrofurans. Ind J Chem 1974, 12: 336-43.
136. Mortensen, D.S., Rodriguez, A.L., Sun, J., Katzenellenbogen, B.S., Katzenellenbogen, J.A. Furans with basic side chains: Synthesis and biological evaluation of a novel series of antagonists with selectivity for estrogen receptor α. Bioorg Med Chem Lett 2001, 11: 2521-4.
137. Ray, S., Rastogi, R., Kumar, A. Current status of estrogen receptor. Prog Drug Res (In press).
138. Dardes, R.C., Jordan, V.C. Novel agents to modulate estrogen actions. Brit Med Bull 2000, 56: 773-86.
139. Levenson, A.S., Mac Gregor Schafer, J.I., Bentrem, D.J., Pease, K.M., Jordan, V.C. Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351. J Steroid Biochem Mol Biol 2001, 76: 61-70.
140. Shian, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard, D.A., Greene, G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95: 927-37.
141. Brzozowski, A.M., Pike, A.C.W., Dauter, Z. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389: 753-8.
142. Clark, J.H., Markaverich, B.M. The agonistic-antagonistic properties of clomiphene: A review. Pharmacol Ther 1981, 15(3): 467-519.
143. Mehrotra, P.K., Karkun, J.N. Studies on physiology and biochemistry of female genital tract: Response of uterus, cervix and vagina of albino rats to cis- and trans clomiphene in the presence or absence of estrogen. Ind J Exp Biol 1973, 11: 7-14.
144. Emmens, C.W. Oestrogenic, anti-oestrogenic and antifertility activities of various compounds. J Reprod Fertil 1965, 2: 277-83.
145. Roy, S., Mahesh, V.B., Greenblatt, R.B. Effects of clomiphene on the physiology of reproduction in the rat. I. Changes in the hypophyseal-gonadal axis. Acta Endocr 1964, 47: 645-56.
146. Watnick, A.S., Neri, R.O. Biological properties of three ovulation inducers, stilboestrol, clomiphene and F 6066. Acta Endocr 1968, 59: 611-21.
147. Taubert, H.-D., Schwantje, R., May, E. Induction of ovulation with clomiphene and related agents in the pseudo pregnant rat. Acta Endocr 1969, 60(Suppl. 138): 202.
148. Ruenitz, P.C. Rabbit liver microsomal metabolism of enclomiphene. Drug Metab Dispos 1981, 9(5): 456-60.
149. Courtney, K.D., Valerio, D.A. Teratology in the macaca mulatta. Teratology 1968, 1(2): 163-72.
150. a) Greenblatt, R.B. Chemical induction of ovulation. Fertil Steril 1961, 12: 402-4.
151. b) Goldstein, S.R., Siddhanti, S., Ciaccia, A.V., Plouffe, L. Jr. A pharmaco logical review of selective oestrogen receptor modulators. Hum Reprod Update 2000, 6(3): 212-24.
152. a) Tavaniotou, A., Albano, C., Smitz, J., Devroey, P. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist. Fertil Steril 2002, 77(4): 733-7.
153. b) Fisher, S.A., Reid, R.L., Van Vugt, D.A., Casper, R.F. A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 2002, 78(2): 280-5.
154. Kamboj, V.P., Ray, S., Dhawan, B.N. Centchroman. Drugs Today 1992, 28: 227-32.
155. Singh, M.M. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone related clinical disorders. Med Res Rev 2001, 21: 302-47.
156. Bolger, J.W. (3M Pharmaceuticals). Process for preparation of substituted 3,4-(diphenyl) chromans. US 3822287.
157. Salman, M., Ray, S., Anand, N., Agarwal, A.K., Singh, M.M., Setty, S.S., Kamboj, V.P., Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity. J Med Chem 1986, 29(9): 1801-3.
158. Ray, S., Sarkhel, S., Maulik, P.R., Lobkovsky, E., Clardy, J. Crystal and molecular structure of 7-methoxy-2,2-dimethyl-3-phenyl-4-(4-hydroxyphenyl)-2H-benzopyran. Acta Cryst 1998, C54: 134-6.
159. Kamboj, V.P., Setty, B.S., Chandra, H., Roy, S.K., Kar, A.B. Biological profile of centchroman - A new post coital contraceptive. Ind J Exp Biol 1977, 15(12): 1144-50.
160. Dhawan, B.N., Srimal, R.C. Anti-inflammatory and some other pharmacological effects of 3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(β -pyrrolidinoethoxy)-phenyl]-7-methoxy-chroman (centchroman). Br J Pharmacol 1973, 49: 64-73.
161. Chak, I.M., Dua, P.R., Kar, K., Srimal, R.C., Dhawan, B.N. Acute toxicity and pharmacology of centchroman. Ind J Exp Biol 1977, 15(12): 1159-61.
162. Nigam, P.K., Malaviya, B., Chowdhury, S.R., Kamboj, V.P., Chandra, H. Effect of long term centchroman treatment on plasma steroid and peptide hormones in female rhesus monkeys. Contraception 1985, 32(3): 283-300.
163. Vaidya, R.A., Joshi, V.M., Maherji, P., Rege, N.R., Betrabet, S., Joshi, L.R., Sheth, A.R., Devi, P.K. Activity profile of centchroman in healthy female volunteers. Ind J Exp Biol 1977, 15(12): 1173-6.
164. Singh, M.M., Bhalla, V., Wadhwa, V., Kamboj, V.P. Effect of centchroman on tubal transport and embryonic development in rats. J Reprod Fertil 1986, 76: 317-24.
165. Singh, M.M., Wadhwa, V., Sethi, N., Kamboj, V.P. Viability and development of "tube-locked" mouse embyos. J Reprod Fertil 1983, 68: 165-70.
166. Singh, M.M., Kamboj, V.P. Effect of centchroman on pre-implantation embryonic development and tubal transport in mice. Biol Reprod 1981, 25: 171-80.
167. Ratna, S., Roy, S.K., Ray, S., Kole, P.L., Salman, M., Madhusudan, K.P., Sircar, K.P., Anand, N. Centchroman: In vitro metabolism by rat liver homogenate. Drug Dev Res 1986, 7(2): 173-8.
168. 14C] chroman. J Lab Comp Radiopharm 1979, 26(2): 373-5.
169. Ratna, S., Mishra, N.C., Ray, S., Roy, S.K. Centchroman: Tissue distribution and excretion profile in albino rats after oral and intravenous administration. J Basic Appl Biomed 1994, 2(3): 31-6.
170. Paliwal, J.K., Gupta, R.C., Grover, P.K., Asthana, O.P., Srivastava, J.S., Nityanand, S. High-performance liquid chromatographic (HPLC) determination of centchroman in human serum and application to single-dose pharmacokinetics. Pharm Res 1989, 6(12): 1048-51.
171. Mukerjee, S.S., Sethi, N., Srivastava, G.N., Roy, A.K., Nityanand, S., Mukherjee, S.K. Chronic toxicity studies of centchroman in rats and rhesus monkeys. Ind J Exp Biol 1977, 15: 1162-6.
172. Mukhopadhyay, A., Gupta, S., Ray, S., Giri, A.K. Anticlastogenic effects of centchroman and its enantiomers in Swiss albino mice. I. Acute study and their comparison with tamoxifen. Cancer Lett 1999, 144: 137-43.
173. Gupta, S., Mukhopadhyay, A., Ray, S., Giri, A.K. Comparative antimutagenic effects of d- and l-centchroman and their comparison with tamoxifen in salmonella assay. Mutation Res 1999, 445: 1-8.
174. Giri, A.K., Mukhopadhyay, A., Sun, J., Hsie, A.W., Ray, S. Antimutagenic effects of centchroman - A contraceptive and a candidate drug for breast cancer in multiple mutational assays. Mutagenesis 1999, 14(6): 613-9.
175. Mukhopadhyay, A., Ray, S., Giri, A.K. Anticlastogenic effects of d- and l-centchroman in Swiss albino mice. 2. Subcute study in vivo and comparison with tamoxifen. Cytobios 2001, 106(412): 77-86.
176. Paliwal, J.K., Grover, P.K., Asthana, O.P., Nityanand, S., Gupta, R.C. Excretion of centchroman in breast milk. Br J Clin Pharmacol 1994, 38: 485-6.
177. Bedford, G.R., Richardson, D.N. Preparation and identification of cis and trans isomers of a substituted triarylethylene. Nature 1966, 212: 733-4.
178. Robertson, D.W., Katzenellenbogen, J.A., Long, D.J., Rorke, E.A., Katzenellenbogen, B.S.J. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. Steroid Biochem 1982, 16: 1-13.
179. Fromson, J.M., Pearson, S., Bramah, S. The metabolism of tamoxifen (ICI 46, 474). Part I: In laboratory animals. Xenobiotica 1973, 3: 693-709.
180. 14C-labelled tamoxifen in spayed female mice. Rev Endocr-Relat Cancer 1982, 9(Suppl.): 233-9.
181. 14C-labelled tamoxifen in spayed female mice. Acta Pharmacol Toxicol 1982, 50: 161-8.
182. Fromson, J.M., Pearson, S., Bramah, S. The metabolism of tamoxifen (ICI 46, 474). Part I: In laboratory animals. Xenobiotica 1973, 3: 711-4.
183. Adam, H.K., Douglas, E.J., Kemp, J.V. The metabolism of tamoxifen in humans. Biochem Pharmacol 1979, 27: 145-7.
184. Adam, H.K., Patterson, J.S., Kemp, J.V. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep 1980, 64: 761-4.
185. Kemp, J.V., Adam, H.K., Wakeling, A.E., Slater, R. Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 1983, 32(13): 2045-52.
186. Foster, A.B., Griggs, L.J., Jarman, M., van Maanen, M.S., Schulten, H.-R.
187. Reunitz, P.C., Bagley, J.R., Pape, C.W. Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab Dispos 1984, 12: 478-83.
188. McCague, R., Seago, A. Aspects of metabolism of tamoxifen by rat liver microsomes. Biochem Pharmacol 1986, 35: 827-34.
189. Lyman, S.D., Jordan, V.C. In: Metabolism of Nonsteroidal Antiestrogens in Estrogen/Antiestrogen Action and Breast Cancer Therapy. Jordan, V.C. (Ed.). University of Wisconsin Press: Madison 1986, 191-219.
190. Mani, C., Gelboin, H.V., Park, S.S., Pierce, R., Parkinson, A., Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos 1993, 21: 645-56.
191. Lim, C.K., Yuan, Z.-X., Lamb, J.H., White, I.N.H., De Matteis, F., Smith, L.L. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 1994, 15: 589-93.
192. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J., Poon, G.K. α-Hydroxytamoxifen a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res 1994, 54: 5518-22.
193. Poon, G.K., Chui, Y.C., McCague, R., Lonning, P.E., Feng, R., Rowlands, M.G., Jarman, M. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos 1993, 21: 1119-24.
194. Poon, G.K., Walter, B., Lonning, P.E., Holton, M.N., McCague, R. Identification of tamoxifen metabolites in human Hep G2 cell line human liver homogenate and patients on long-term therapy for breast cancer. Drug Metab Dispos 1995, 23: 377-82.
195. Dorssers, L.C.J., van der Flier, S., Brinkman, A. et al. Tamoxifen resistance in breast cancer. Drugs 2001, 61(12): 1721-33.
196. Cole, M.P., Jones, C.T., Todd, J.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br J Cancer 1971, 25: 270-5.
197. Fisher, B., Costantino, J.P., Wickerham, D.L. et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90: 1371-88.
198. Killackey, M.A., Hakes, T.B., Pierce, V.K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985, 69: 237-8.
199. Raghow, S., Hooshdaran, M.Z., Katiyar, S., Steiner, Ms. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002, 62(5): 1370-6.
200. Valavaara, R., Pyrhönen, S., Heikkinen, M. et al. Safety and efficacy of toremifene in breast cancer patients. A phase II study. J Steroid Biochem 1990, 36: 229-31.
201. Gunderson, S. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study. J Steroid Biochem 1990, 36: 233-4.
202. Hietanen, T., Baltina, D., Johansson, R. et al. High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study. Breast Cancer Res Treat 1990, 16(Suppl.): S37-S40.
203. Modig, H., Borgstrom, S., Nilsson, I., Westman, G. Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication. J Steroid Biochem 1990, 36: 235-6.
204. a) Hayes, D.F., Van Zyl, J.A., Hacking, A. et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995, 13: 2556-66.
205. b) Pyrhonen, S., Valavaara, R., Modig, H. et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: A randomized double-blind, the 'Nordic' phase III study. Br J Cancer 1997, 76: 270-7.
206. Jones, C.D. (Eli Lilly and Company). Antiestrogenic and antiandrugenic benzothiophene. US 4418068.
207. Delmas, P.D., Bjarnason, N.H., Mitlak, B.H. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337: 1641-7.
208. Saitta, A., Morabito, N., Frisina, N. et al. Cardiovascular effects of raloxifene hydrochloride. Cardiovasc Drug Rev 2001, 19(1): 57-74.
209. Wenger, N.K. Cardiovascular effects of raloxifene: The potential for cardiovascular protection in women. Diabetes Obesity Metab 2002, 4: 166-76.
210. Sismondi, P., Biglia, N., Roagna, R., Ponzone, R., Ambroggio, S., Sgro, L., Cozzarella, M. How to manage the menopause following therapy for breast cancer. Is raloxifene a safe alternative? Eur J Cancer 2000, Suppl. 4: S74-6.
211. Cohen, I.R., Sims, M.L., Robbins, M.R., Lakshmanan, M.C., Francis, P.C., Long, G.G. The reversible effects of raloxifene on luteinizing hormone levels and ovarian morphology in mice. Reprod Toxicity 2000, 14: 37-47.
212. Khovidhunkit, W., Shoback, D.M. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999, 130: 431-9.
213. Yang, N.N., Venngopalan, M., Hardikar, S. et al. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996, 273: 1222-5.
214. Gize, E.A., Venngopalan, M., Glasebrook, A.L. et al. Characterization of raloxifene binding and transactivation properties of the estrogen receptor-β (ERα). J Bone Miner Res 1997, Suppl. 12: S460.
215. Yang, N.N., Bryant, H.U., Hardikar, S. et al. Estrogen and raloxifene stimulate transforming growth factor-β 3 gene expression in rat bone: A potential mechanism for estrogen or raloxifene mediated bone maintenance. Endocrinology 1996, 137: 2075-84.
216. Raloxifene package insert. Eli Lilly and Company, 1997.
217. Pavo, I., Masanauskaite, D., Rojinskaya, L. et al. Effects of raloxifene (RLX) vs placebo (PL) on bone mineral density (BMD) in postmenopausal women in the absence of calcium supplimentation. J Bone Miner Res 1999, 14(Suppl. 1): 3410.
218. Barrett-Connor, E., Grady, D., Sashegyi, A. et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA - J Am Med Assoc 2002, 287(7): 847-57.